Takeda Wants Orexigen To Bear $200 Million Contrave CV Trial Cost
This article was originally published in The Pink Sheet Daily
Executive Summary
Takeda initiated dispute resolution proceedings against Orexigen demanding the smaller company pay the full cost of a new cardiovascular outcomes trial after Orexigen’s controversial data disclosure from the initial Light study.